AUS
NZ
UK
CA
USA
IND
Highlights
- Trump’s win could bring shifts in healthcare policies and drug pricing.
- Robert F. Kennedy Jr.’s involvement hints at a disruptive health agenda.
- Changes may affect the FDA, M&A oversight, and drug pricing approaches.
With Donald Trump’s recent victory in the United States presidential election, potential changes may be on the horizon for federal health agencies and the industries they regulate. Trump has emphasized his commitment to “making America healthy again,” suggesting a possible shake-up within health policy. His collaboration with Robert F. Kennedy Jr., a vocal critic of certain pharmaceutical practices, raises questions about what direction these potential reforms might take. Trump expressed support for Kennedy’s involvement in a campaign speech, noting, “I’m going to let him go wild on health, food, and medicines.” While the details remain uncertain, these comments indicate possible unconventional shifts in policy.
Kennedy’s prospective role in shaping healthcare policy has drawn considerable attention, especially regarding Trump’s plans for the Food and Drug Administration (FDA). Previously, Trump appointed Scott Gottlieb and Stephen Hahn to lead the FDA. His administration occasionally pressured the agency to consider unproven COVID-19 treatments but also achieved notable advancements with "Operation Warp Speed," which expedited vaccine development.
Kennedy’s potential agenda could steer healthcare policy in an unprecedented direction. In an interview with NPR, he emphasized tackling “corruption” in regulatory bodies, aiming to restore evidence-based science and address what he describes as a “chronic disease epidemic.” He has also expressed interest in promoting stem cell treatments and nutraceuticals, areas that have faced skepticism from some in the medical community.
Industry experts are watching closely to see if Kennedy’s role becomes official, as this could signal a shift from traditional regulatory practices. However, gaining Senate confirmation for Kennedy or others with similar views may present challenges. According to Jeffrey Jonas, former CEO of Sage Therapeutics, any appointee should bring science-driven expertise to the table, given the highly regulated nature of the pharmaceutical industry.
In terms of mergers and acquisitions (M&A), biotech executives are cautiously optimistic. Changes in leadership at agencies like the Federal Trade Commission (FTC) could ease the regulatory landscape for biotech deals, crucial for growth and innovation. Under current chair Lina Khan, the FTC has implemented stricter merger guidelines and recently scrutinized high-profile transactions, such as Amgen’s (NASDAQ:AMGN) US$28 billion acquisition of Horizon Pharmaceuticals.
Beyond agency leadership, a Trump administration could revisit federal drug pricing policies. During his first term, Trump introduced policies to lower drug costs, such as the “favoured nations” proposal, linking Medicare reimbursements to international pricing. Though the initiative stalled, experts like Jonas suggest it could resurface in modified forms, impacting the pharmaceutical industry’s pricing strategies.
As this new administration takes shape, the pharmaceutical and healthcare sectors are preparing for potential regulatory adjustments that could impact drug pricing, agency operations, and M&A within the industry.
